← All trials
NCT05292664
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Apr 2, 2025
- Completion date
- Apr 2, 2027
- First posted
- Mar 23, 2022
- Last posted
- Nov 30, 2022
- Enrollment
- 92
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- AbbVieCollaborator
- Harvard UniversityCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversitySponsor investigator
- Gateway for Cancer ResearchCollaborator
- ServierCollaborator
- University of Colorado, DenverCollaborator
- Harvard UniversityOfficial
- Children's Cancer Research Fund United StatesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.